Biograil

About Biograil

Biograil is a pharmaceutical company in the pre-clinical stage, focusing on transforming injectable drugs into easy-to-use oral capsules. This innovative approach could revolutionize the vast market of injectable pharmaceutical products, making medication more accessible and convenient for patients.

Biograil operates in the pharmaceutical industry, specifically in drug delivery technology. Its primary clients are likely to be other pharmaceutical companies looking to improve the delivery methods of their drugs, and potentially healthcare providers and patients who would benefit from more convenient drug administration.

The company's business model revolves around the development and licensing of its proprietary BIONDD™ Technology. This technology has already shown promise in pre-clinical models, and Biograil is preparing for Phase 1 clinical trials. The company has also formed an international scientific advisory board to further optimize this technology.

Biograil generates revenue through collaboration and licensing agreements with other pharmaceutical companies. For instance, it has signed a Collaboration and License Agreement with Eli Lilly, a major player in the pharmaceutical industry. Additionally, the company has received non-dilutive funding from Innobooster, a government grant, to support its research and development activities.

In summary, Biograil is a promising startup in the pharmaceutical industry, with a unique approach to drug delivery that could significantly impact the market for injectable drugs.